Status:
ACTIVE_NOT_RECRUITING
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Conditions:
Membranous Nephropathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a non-pharmacological interventional monocentric study to primarily assess the levels of circulating phospholipase A2 receptor (PLA2R)-specific B cells in patients with PLA2R-mediated MN enrol...
Detailed Description
Primary Membranous Nephropathy (MN) is the most frequent cause of Nephrotic Syndrome (NS) in adults. Even though 30% of affected patients may experience spontaneous remission of the disease, MN-associ...
Eligibility Criteria
Inclusion
- Patients
- Patients enrolled in the ORION and MONET studies who have who provided written informed consent to store their samples collected during the follow-up at the Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Ranica (BG).
Exclusion
- No written informed consent to store their samples collected during the follow-up at the Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Ranica (BG).
- Volunteers
- Inclusion criteria:
- Adult males and females.
- Written informed consent.
- Exclusion criteria:
- History of renal diseases, autoimmune disorders, diabetes mellitus, current allergies.
- Subjects who have taken antibiotics, anti-inflammatory drugs, or antihistamines within the past 7 days.
Key Trial Info
Start Date :
August 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT06994468
Start Date
August 14 2025
End Date
July 1 2027
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
Ranica, BG, Italy, 24020